[Preprint] Estudo randomizado aberto | Baricitinibe é não inferior ao tocilizumabe em pacientes internados com COVID-19 grave.
21 Jun, 2022 | 13:01hConteúdos relacionados:
WHO recommends two new drugs to treat COVID-19 – World Health Organization
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 – New England Journal of Medicine
Comentário no Twitter
Preprint⚡⚡
Baricitinib Vs Tocilizumab open label RCT
Baricitinib was non-inferior to tocilizumab with regards to the composite outcome of mechanical ventilation or death by day 28 and the time to discharge by day 28 in patients with severe #COVID19 https://t.co/sQkhATkjEd— Antibiotic Steward Bassam Ghanem🆔🔥 (@ABsteward) June 16, 2022